About ERN CRANIO
ERN CRANIO is the European Reference Network for rare and/or complex craniofacial anomalies and ear, nose and throat (ENT) disorders. ERN CRANIO is a network of expert multi-disciplinary healthcare professionals from specialised healthcare providers across Europe. The network was officially launched in March 2017.
ERN CRANIO is a network of expert multi-disciplinary healthcare professionals from specialised healthcare providers across Europe (‘ERN CRANIO members’). ERN CRANIO has 35 member hospitals across 15 European member states.
ERN CRANIO aims to pool together disease-specific expertise, knowledge and resources from across Europe to achieve health goals that may otherwise be unachievable in a single country.
ERN CRANIO also seeks to reduce health inequalities across Europe by standardising practices and making high-quality care, information and resources accessible to healthcare providers, patients and their families/carers across Europe, regardless of where they are located.
ERN CRANIO organisation and structure
Want to know more about how we are organised and coordinated? Click on the button below for more information!
ERN CRANIO collaborations and networking partners
In pursuing our mission, vision and aims, the ERN CRANIO network works together with other expert rare disease networks and societies. ERN CRANIO is part of the ERICA consortium, in which all 24 ERNs take part, where we work together in all ERNs on research and innovation. On a European level, ERN CRANIO also takes part in the European Joint Programme on Rare Diseases (EJP RD).
ERN CRANIO makes use of the networks through surgical societies such as the European Society of Craniofacial Surgery (ESCFS), the European Cleft Palate Craniofacial Association (ECPCA), and the European Society for Pediatric Neurosurgery (ESPN).
Moreover, ERN CRANIO collaborates with EURORDIS rare diseases Europe. EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of over 1000 rare disease patient organisations from 74 countries that work together to improve the lives of over 300 million people living with a rare disease globally.